Prostatitis Antigens Diagnostic Assay for CPPS Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing chronic pelvic pain syndrome (CPPS) are inadequate, as they rely on subjective pain reports and lack specific biomarkers, leading to unclear etiology and ineffective therapies.
Innovation Solution
Identification of prostatitis-associated antigens (PAA) such as semenogelin and SVS2, which are used to develop diagnostic assays and treatments by measuring immune responses in individuals, allowing for differentiation from prostate cancer and other disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods relying on subjective pain reports are used, then the diagnostic process is simple and non-invasive, but the measurement precision and reliability of diagnosis are insufficient
Solution Approach 1:
The patent introduces prostatitis-associated antigens (PAA) as intermediary biomarkers that mediate between the disease state and the diagnostic measurement. These antigens serve as objective intermediaries that can be detected in biological samples, replacing subjective pain reports with measurable immunological responses, thereby improving diagnostic precision without requiring complex invasive procedures
Solution Approach 2:
The patent replaces the mechanical/subjective assessment method (pain reporting) with an immunological/biochemical measurement system. By detecting immune responses to PAA through laboratory assays, the diagnosis transitions from subjective mechanical assessment to objective biochemical measurement, enhancing reliability while maintaining operational simplicity
2Reliability
If prostate biopsy is performed to evaluate for prostate cancer, then the diagnosis of prostate cancer can be confirmed, but invasive procedures increase patient risk and complexity
Solution Approach 1:
The patent enables preliminary diagnostic assessment through detection of immune responses to PAA before proceeding to invasive biopsy. By first evaluating the presence and level of anti-PAA antibodies or T-cell responses, clinicians can identify patients with high probability of prostatitis, thereby avoiding unnecessary invasive biopsies in those cases and reserving them for patients where cancer suspicion remains high
Solution Approach 2:
The patent introduces PAA-specific immune response markers as intermediary diagnostic indicators that provide information about prostate pathology without requiring direct tissue sampling. These immunological markers serve as safe intermediaries that reduce the need for harmful invasive procedures while maintaining diagnostic reliability for differentiating prostatitis from prostate cancer
3Productivity
If empiric treatment with antibiotics is administered for CPPS, then treatment can be initiated immediately, but the therapy lacks specificity and clear efficacy
Solution Approach 1:
The patent implements a feedback-based diagnostic approach where detection of anti-PAA immune responses provides information about the likelihood of autoimmune prostatitis. This feedback allows clinicians to tailor treatment decisions: patients with positive anti-PAA responses may benefit from immunomodulatory therapies rather than antibiotics, while those with negative responses may still require empiric antibiotic treatment, thereby improving treatment efficacy through targeted therapy selection
Data Source
AI summary
The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual. Kits suitable for use in performing such diagnostic assays are also provided. The present disclosure further provides methods of treating prostatitis, methods of treating prostate cancer, and methods of treating benign prostatic hyperplasia.